The deal helps move BioNTech’s proposed acquisition of CureVac closer to completion. With the settlement, GSK said it will tender the CureVac shares it owns in support of the $1.25 billion acquisition ...

CureVac Announces Financial Results for the Second Quarter and First Half of 2025 and Provides Business Updates Entered into ...

By entering into a definitive purchase agreement with BioNTech, we intend to unite two highly complementary German companies that are well ...

Germany's CureVac and Britain's GSK have settled a years-long patent dispute with Pfizer and its partner BioNTech over the ...

German biotech firm CureVac (5CV.DE) saw billions of euros wiped from its market value on Thursday after its COVID-19 vaccine proved only 47% effective in an initial trial read-out, denting ...

CureVac had some advantages over the other mRNA vaccines, such as keeping stable for months in a refrigerator. What’s more, compared with its competitors, CureVac’s vaccine used fewer mRNA ...

For CureVac’s co-founder, the biologist Ingmar Hoerr, the company’s Covid-19 vaccine trial is the culmination of a quarter-century’s worth of work with RNA, a molecule that helps turn DNA ...

CureVac's experimental COVID-19 vaccine failed in a pivotal clinical study, the biotech said Wednesday. It's the first late-stage study to flop, with CureVac's vaccine showing 47% effectiveness.

CureVac, the latest experimental coronavirus vaccine, proves just 48 percent effective overall, a disappointing result Company emphasizes that in people 60 and younger, vaccine was 77 percent ...

Germany's CureVac (5CV.DE) is on track to file for European approval of its COVID-19 vaccine as early as this month because high infection rates among trial participants are bringing a read-out on ...

CureVac, latest experimental coronavirus vaccine, proved just 47 percent effective amid spread of variants, preliminary analysis shows The vaccine is the third to use messenger RNA, the technology ...

CureVac is also proceeding, in partnership with GlaxoSmithKline, on the development of another Covid vaccine candidate that is intended to start working more quickly than its first one.